$4.00 0.11 (+2.83%)
11/20/2009 4:00 PM

Santarus, Inc. (SNTS)

CAPS Rating: 3 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Current Price $4.00 Mkt Cap $232.3M
Open $3.89 P/E Ratio 0.00
Prev. Close $3.89 Div. (Yield) N/A (N/A)
Daily Range $3.85 - $4.00 Volume 191,545
52-Wk Range $1.05 - $4.23 Avg. Daily Vol. 265,000

SNTS News and Commentary

Related News and Articles

Caps

How do you think SNTS will perform vs the S&P 500?

Add Stock to Watchlist

All Members

57 Outperform
7 Underperform
 

All-Star Members

13 Outperform
2 Underperform
 

Wall Street

6 Outperform
1 Underperform
 

Top SNTS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

docmase (< 20)
Submitted August 19, 2006

Santarus is a specialty pharmaceutical firm trying to promote a branded form of omeprazole (generic) in a market that is dominated by large pharmaceutical companies with significantly greater resources. The company has managed to grow revenues but… More

2 Comments | Reply | Report this Post
SNTS VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about SNTS.

Recs

0
Member Avatar manucastle (68.11) Submitted: 11/10/2009 4:45:48 AM : Outperform Start Price: $3.95 SNTS Score: +0.84

I have purchased SNTS :-

http://finance.yahoo.com/q?s=snts&.yficrumb=%2FQnGSSWfR3...

Industry: biotech & drugs
EPS = -0.06
EPS EST 1yr = 0.193 2yr = 0.230
PE = na Industry 15.2
PB = 10.56 Industry 2.7
PS = 1.49 Industry 3.5
P/CF = na industry 13.6
P/FCF = na Industry 13.7
Yield 0.0 Industry 0.0
Gross profit margin = 82.2 Industry 51.0
Operating margin = -1.1 Industry -42.3
Net Profit Margin = -1.8 Industry -42.0
ROA = -2.8 Industry -52.3
ROE = -18.5 Industry -14.7
Insider ownership = 0.6
Greenblatt ROC = 4.92
Greenblatt Earnings Yield = 0.00
PosFCF generic % free cash flow yield -4.74%***
Passes 15 of 17 of Mike Klein's metrics
MaxPrice = 10.18 Discount 63%**
Metrics from qtr ending 9/30/2009
Caps rank 3
http://caps.fool.com/Ticker/SNTS.aspx
MC score 243

All good enough for my money. I only suggest stocks that I own !

(See posts 388/584/665/760/1051/1807/2213/3546/3755/4046/4208/4225/4345/4573/4818/5241/5242/5310/5461/5579/
5169/7651 on 'Investment Analysis Clubs / Dynamic Value Investing ' board for extra due diligence applied ). **MaxPrice is a generic version of Mike Klein's Maxprice and ROC and Earnings yields are generic versions of Greenblatt's metrics. *** PosFCF generic % free cash flow yield taken from AAII and posts 5248 and 5253

See 'Investment Analysis Clubs / Dynamic Value Investing' board and my CAPS profile for further excellent companies selling at a discount to Maxprice with excellent current metrics. CAPS only shows my selections over 100Mill (unfortunately due to restricted lower market cap applied by MF CAPS).

As stated on the 'Investment Analysis Clubs /Dynamic Value Investing' board my aim is to obtain up to 50% returns p.a. as Buffett stated he could obtain (3 times) recently. A very difficult task but you can follow along with my buys and sells on my CAPS page, where I put my money where my mouth is . If I perform well I hope you can benefit. If not , feel free to ignore my comments. CAPS allows each and everyone of us to be clinically judged on our stock picking abilities over the LONG TERM.

Please always do your own due diligence before investing.

Manucastle :o)

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar Brian7992 (< 20) Submitted: 8/11/2009 2:29:09 PM : Outperform Start Price: $3.12 SNTS Score: +18.18

Buy me now!

Report this Post 0 Comments | Reply | Permalink

Recs

0
Member Avatar poppinkid (< 20) Submitted: 5/8/2008 9:12:28 PM : Outperform Start Price: $2.51 SNTS Score: +77.37

Highly underrated. GERD treatments are not that effective and LR PPI drugs don't provide immediate relief. Zegrid has a IR formulation that is significantly better than current prescriptions and OTC products. Hence, Schering and Glaxo's interest in co-promotion. This is a 14B market, and 5% of that market will make this an easy 4 bagger. The PAR case is causing hang over, but look for that to resolved and for profitability in 2009.

Report this Post 1 Comment | Reply | Permalink
View All 9 Pitches »

Leaderboard

Find the members with the highest scoring picks in SNTS.

Score Leader

TotoMMB

TotoMMB (99.62) Score: +119.08

The Score Leader is the member with the highest score across all their picks in SNTS.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
TotoMMB 99.62 2/20/2008 2/17/2009 Outperform 3Y $1.96 +104.07% -15.01% +119.08
wp1782 < 20 2/21/2008 Outperform 3W $1.99 +101.01% -16.44% +117.44
RRUI < 20 3/5/2008 Outperform 1Y $2.09 +91.39% -14.35% +105.74 1 Comment
robertvince 69.75 8/8/2007 Outperform 3Y $2.20 +81.83% -22.93% +104.76
xkrlongname 65.17 10/12/2007 Outperform 3Y $2.35 +70.58% -26.49% +97.07
mellonhead727 31.36 7/29/2008 Outperform NS $2.26 +76.99% -9.64% +86.63
PatientTrader 86.85 12/21/2007 Outperform 5Y $2.44 +63.93% -22.62% +86.55
tjdobb2stocks 44.55 12/26/2007 Outperform NS $2.46 +62.60% -23.28% +85.88
pallidum 69.68 10/14/2008 Outperform 1Y $2.10 +90.48% +7.22% +83.25
jloffswold 40.19 5/9/2008 Outperform 3Y $2.43 +64.61% -18.23% +82.84
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackZacks 70.74 11/9/2009 Outperform 3M $3.78 +5.82% -0.13% +5.95 1 Comment
TrackRothCapital 74.09 6/25/2009 Outperform NS $2.86 +39.86% +22.62% +17.24
TrackUBS 88.39 8/5/2008 Outperform NS $2.45 +63.27% -10.83% +74.10
TrackFBRCapitalM 73.72 6/29/2007 Outperform NS $5.37 -57.73% -16.96% -40.76 7/10/2008 @ $2.27
TrackRodmanRen < 20 6/29/2007 Outperform NS $5.37 -25.51% -23.66% -1.85
TrackMerriman < 20 5/24/2007 Outperform NS $6.83 -62.81% -7.70% -55.11 6/5/2008 @ $2.54
TrackWedbush < 20 10/19/2006 Outperform NS $8.85 -54.80% -14.81% -39.99
TrackSusquehanna 73.96 10/19/2006 Underperform NS $8.85 -38.08% +10.98% +49.06 7/2/2007 @ $5.48
TrackJimCramer 36.31 10/19/2006 Underperform 3W $8.97 -55.41% -14.91% +40.50
TrackRBCCapMkts 82.07 8/9/2006 Outperform NS $5.30 -24.53% -9.16% -15.37
TrackJimCramer 36.31 3/24/2006 Outperform 3W $6.25 +43.52% +4.91% +38.61 10/20/2006 @ $8.97

Featured Broker Partners